The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR)

No abstract

Using solid phase-assisted synthesis and purification, a 49 member library of analogs of the mammary tumor chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been prepared. After prescreening for growth inhibitory activity in human mammary tumor cells (MCF-7) in culture, most of those analogs which showed activity (12 of them) were assayed for apoptosis-inducing activity in the MCF-7 cells. At least 3 of the analogs (13, 24, and 28) showed activity approaching that of 4-HPR.The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; 1) was developed a number of years ago and has shown promise as a breast cancer chemopreventive agent in animals.

No abstract

Supplementary Figure 1 from The Unhydrolyzable Fenretinide Analogue 4-Hydroxybenzylretinone Induces the Proapoptotic Genes <i>GADD153</i> (<i>CHOP</i>) and <i>Bcl-2–Binding Component 3</i> (<i>PUMA</i>) and Apoptosis that Is Caspase- Dependent and Independent of the Retinoic Acid Receptor